van Schaik IN, et al. – This multicenter, randomized, double–blind, placebo–controlled trial was performed to assess IgPro20 subcutaneous immunoglobulin (SCIG) as a maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). As maintenance treatment, IgPro20 was efficacious and well–tolerated in CIDP.

• The physicians conducted a randomized, double-blind trial in CIDP patients (n=172) investigated 0.2 and 0.4 g/kg weekly doses of IgPro20 vs. placebo.
• Percentage of patients with CIDP relapse/withdrawal during 24-weeks of treatment determined by Inflammatory Neuropathy Cause and Treatment score was the primary outcome.
• Grip strength and patient satisfaction were included as secondary endpoints.

• The physicians found that both IgPro20 doses significantly reduced rate of CIDP relapse/withdrawal vs. placebo.
• With Hizentra, grip strength remained stable, but deteriorated with placebo.
• Over IVIG, most subjects preferred SCIG.
• In intensity, local reactions were mild or moderate, reported in 33% of IgPro20-treated patients.